Editas Medicine (EDIT) Competitor Comparison
We are evaluating the key criteria listed to compare Editas Medicine (EDIT) against its competitors in the Biotechnology industry.
Market Capitalization
148 / 368Gross Profits
255 / 278Total Revenue
151 / 300EBITDA
285 / 337Free Cashflow
279 / 352Quick Ratio
156 / 357Earnings per Share
239 / 359Dividend yield
0 / 6Total Cash
92 / 358Performance 3 years
336 / 368Performance 5 years
328 / 368Performance 10 years
256 / 368Linearity 3 years
266 / 368Linearity 5 years
187 / 368Linearity 10 years
91 / 367Total Rank
314 / 368Dividend Rank
114 / 368Valuation Rank
204 / 368Piotroski Rank
350 / 368Muliplier Rank
335 / 368Market Capitalization - EDIT ranking 148 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.